Purpose To compare the surgical outcomes of repeat deep sclerectomy (DS) and the Baerveldt glaucoma implant (BGI) in eyes with failed primary deep sclerectomy. Design A retrospective comparative case-control study. Methods Fifty-eight eyes of 56 glaucoma patients with previously failed DS underwent BGI (group BGI) and 58 eyes of 55 patients underwent repeat DS (group DS) at a tertiary referral centre. Visual acuity, intraocular pressure (IOP), number of glaucoma medications, surgical failure rates and complication rates were compared between groups. Surgical failure was defined as loss of IOP control, loss of light perception, or need for further glaucoma surgery. Results Baseline demographics were similar between groups. Preoperatively, median IOP was lower in the DS than the BGI group (19 mmHg versus 21 mmHg, p=0.10). Postoperatively at year 1, median IOP was significantly higher in the DS than BGI group (14 mmHg versus 11 mmHg, p=0.02). There were no differences between the DS and BGI groups in mean number of medications preoperatively (2.3 versus 2.6) or postoperatively (1.3 versus 1.1). Complication rates were significantly higher in the DS group [41 % (n=24) versus 14 % (n=8); p=0.01]. The failure rate at 1 year was higher in eyes with repeat DS than in eyes with BGI (30 vs. 21 %, respectively; p=0.07). Conclusions Baerveldt implants were more effective in lowering IOP and resulted in significantly fewer complications than repeat deep sclerectomy in eyes with previously failed deep sclerectomy.
Introduction
Deep sclerectomy (DS) is a form of non-penetrating glaucoma filtration surgery indicated in medically uncontrolled glaucoma. It involves the removal of a deep scleral flap, the external wall of Schlemm's canal and corneal stroma, leaving behind the anterior trabeculum and Descemet's membrane, thereby creating an intrascleral space [1] . A recent Cochrane review revealed no significant difference between primary DS and trabeculectomy in terms of intraocular pressure (IOP) lowering [2, 3] . Furthermore, DS has been associated with fewer postoperative complications, largely due to less surgically induced cataract formation and fewer hypotony-related complications [2] [3] [4] . As DS filtration blebs are prone to scarring, a number of adjunctive techniques, such as intraoperative mitomycin C, bevacizumab, insertion of spacer devices and postoperative Nd:YAG laser goniopuncture, have been used to increase efficacy [5] [6] [7] [8] [9] [10] [11] [12] [13] .
Aqueous shunts have traditionally been reserved for patients with recalcitrant glaucoma or those in whom previous filtration surgery had failed [14] . These devices have been associated with several complications as a result of uncontrolled hypotony in the initial postoperative period and longterm corneal decompensation and tube erosion. More recently, attempts have been made to reduce complication rates by modifying surgical techniques to improve IOP control [14] [15] [16] and to avoid tube-corneal contact [15, 17, 18] .
There is no current consensus regarding surgical approach in eyes with previously failed glaucoma surgery. Studies have shown that after filtration surgery has failed once, the success rates with repeat surgery are lower [19] [20] [21] [22] [23] [24] . The Tube versus Trabeculectomy (TVT) study highlighted the greater efficacy of shunt implantation compared with trabeculectomy in eyes with previous surgery [19, 20] . To the best of our knowledge, there have been no studies reporting outcomes of glaucoma surgery following failed DS, and in particular, no comparative studies examining the success of DS versus aqueous shunts in eyes with previously failed DS.
To this end the authors set out to compare the surgical outcomes for the Baerveldt glaucoma implant (BGI) versus repeat DS in eyes with previously failed DS.
Methods
Eligible patients were identified from the diagnostic database of the Glaucoma Unit of Jules-Gonin Eye Hospital, Lausanne, Switzerland. All eyes had medically uncontrolled glaucoma and one failed DS, followed by either repeat DS (group DS) or Baerveldt glaucoma implant (BGI group). Eyes with previous trabeculectomy, other forms of glaucoma surgery (other than DS), encircling band retinal surgery, or intraoperative perforation of the trabeculo-Descemet membrane were excluded.
BGI group All eyes that underwent Baerveldt tube (350 mm 2 ) surgery following one failed DS were identified from a consecutive surgical database. All surgeries were performed by an experienced glaucoma shunt surgeon (ES) between January 2009 and January 2011.
DS group All eyes that underwent two consecutive deep sclerectomies were identified from a separate consecutive surgical database, and surgeries were performed between 1998 and 2008 (repeat DS was not performed at our institution after 2008). Repeat DS was performed by two surgeons experienced in non-penetrating glaucoma surgery (AM, ER).
All medical notes were reviewed and data collected for patient demographics and postoperative outcomes. This retrospective study was approved by the ethical committee of the Canton of Vaud, and conformed to the tenets of the Declaration of Helsinki. All eyes underwent slit lamp biomicroscopy, visual acuity (VA) test, measurement of intraocular pressure (IOP) using the Goldmann applanation tonometer, and fundus examination. The surgical techniques and postoperative protocols have been detailed in previous reports [1, 7, 10, 15] .
Summary of surgical procedure: Baerveldt shunt implant (described in detail elsewhere [15] )
A peritomy was performed in the superotemporal quadrant. The superior and lateral rectus muscles were identified and freed from the surrounding Tenon's capsule. The tube plate was placed under the bellies of the recti and secured to the sclera with 9.0 Prolene sutures. The tube was inserted into the anterior chamber (AC) via scleral entry just posterior to the limbus. An occluding stent (3.0 Supramid suture) was inserted intraluminally to obstruct aqueous outflow; however, if there was insufficient flow restriction, a ligation suture was placed around the distal end of the tube. Processed human pericardium (Tutoplast ® pericardium; IOP Ophthalmics, Costa Mesa, CA, USA) was placed over the extraocular portion of the tube and secured with one 10.0 nylon overlying mattress suture.
Patients who underwent combined surgery underwent standard small-incision phacoemulsification via a temporal approach prior to insertion of the tube into the AC.
Postoperative protocol for the Baerveldt tube
Postoperative management included preservative-free topical dexamethasone (Dexafree ® UD 0.1 %) 8 times daily, tapered over 4-6 weeks, and ofloxacin (Floxal ® UD, Bausch & Lomb, Zug, Switzerland) 4 times daily. Argon laser suture lysis (LSL) of the nylon ligature suture was performed using a Hoskins lens≥1 month after surgery if IOP lowering was clinically required. If sufficient IOP reduction was not obtained after 12 weeks, the occluding stent was either retracted or removed, depending on risk factors for hypotony.
Summary of surgical procedure: repeat deep sclerectomy (described in detail elsewhere [1, 7, 10] ) DS was performed in the superior quadrant. A superficial fornix-based conjunctival flap was created and the sclera exposed. A superficial scleral flap measuring 5x5 mm was fashioned using a diamond knife and extended into the peripheral clear cornea. Mitomycin C (0.2 mg/mL) was applied under the conjunctiva and scleral flap for 2 min. The inner wall of Schlemm's canal was removed and a collagen implant sutured to the scleral bed. The superficial scleral flap was secured over the implant with two loosely tightened sutures. Repeat surgery was carried out adjacent to the primary surgical site in either the superotemporal or superonasal quadrant.
Patients who underwent combined surgery underwent standard small-incision phacoemulsification via a temporal approach following dissection of the scleral flap, which was sutured after phacoemulsification.
Postoperative protocol for DS
Postoperative management included topical dexamethasone (1 mg) and tobramycin (3 mg) (Tobradex ® ; Alcon Switzerland, SA, Rotkreuz, Switzerland) 4 times daily. Topical steroids were tapered over 4-12 weeks. If IOP lowering was clinically required, laser goniopuncture was performed (Microruptor II; Lasag AG, Thun, Switzerland; in Q-switch mode at 5 to 8 mJ), which created microscopic holes in the trabeculo-Descemet membrane allowing direct passage of aqueous from the anterior chamber into the intrascleral space. If bleb scarring was observed, bleb needling was performed (at the slit lamp) and/or an antimetabolite injection was administered (0.1 mL 50-mg/mL solution 5-FU/ 0.05 mL 0.2 -mg/ml solution mitomycin C) Failure criteria (goniopuncture, needling, stent removal or laser suture lysis) were performed within the first 6 months, failure was determined following the last postoperative intervention.
Complications
Macroscopic hyphema was considered present when >1 mm blood was seen in the AC. Persistent hypotony was defined as IOP ≤5 mmHg on two consecutive visits ≥6 weeks apart.
The presence of choroidal effusion/hemorrhage and maculopathy was assessed by routine dilated fundus examination.
Statistical analysis
Analysis was performed using R version 2.15.1 software. Patients lost to follow-up were censored at their last visit. Missing data was assumed to occur at random. Since the parameters reported here (e.g., IOP, GM and VA) are not normally distributed, median and interquartile range (IQR) were reported. Mean values were included to enable comparisons with other studies.
Results
A total of 58 eyes of 56 patients underwent BGI implant surgery, and 58 eyes of 55 patients underwent repeat DS. Baseline demographics and follow-up for the two groups are summarised in Table 1 Fig. 1 ).
Baseline and follow-up IOP measurements are reported in Tables 1 and 2 and in Fig. 1 . Both DS and BGI led to IOP lowering, but the IOP profiles differed markedly between groups (Fig. 1) . During the early postoperative period, a larger IOP reduction was observed in the DS group (day 1: median IOP 9 mmHg versus 19 mmHg; Fig. 1) . At week 1, IOP in 13 eyes (22 %) from the DS group fell within the hypotony range (≤5 mmHg), versus one eye (2 %) from the BGI group. Conversely, in the BGI group, IOP in 14 eyes (24 %) fell within the hypertony range (>21 mmHg), versus one eye (2 %) from the DS group. These significant differences in early postoperative IOP between groups persisted until week 6 (p<0.02). As the majority of the occlusive stent removal was performed (BGI group) between 6 weeks and 6 months postoperatively, a large reduction in median IOP was observed in the BGI group at 3 and 6 months. At month 12, the median IOP in the BGI group was significantly lower than that in the DS group (p=0.02).
Cumulative failure curves are shown in Fig. 2 . Five eyes in the BGI group failed due to insufficient IOP control (<20 % reduction). Seven eyes in the DS group failed due to insufficient IOP control (<20 % reduction n=4; IOP<5 mmHg n=3). Using the Kaplan-Meier analysis to examine failure (accounting for loss of follow-up), at year 1, failure was estimated at 21 % (confidence interval 10-31 %) in the BGI group and 30 % (confidence interval 14-42 %) in the DS group, with the difference approaching statistical significance (p=0.07; Fig. 2) . None of the eyes in the BGI group underwent reoperation during the first year; four eyes in the DS group underwent glaucoma Significance between groups was derived using Mann-Whitney U tests (MWU); ** denotes p<0.01, and * denotes p<0.05 reoperation during the first year (one cyclodiode, one tube, one DS revision, one DS surgery at a different surgical site). Table 1 shows the number of glaucoma medications in each group at baseline and during follow-up. A significant reduction in glaucoma medication use was observed in both groups. There was no difference between groups.
Complication rates differed between the DS and BGI groups [41 % (n=24) versus 14 % (n=8), respectively, p<0.01, chisquare test; Table 3 ]. In the BGI group, three complications were related to hypotony (three cases of choroidal effusion), and three were tube-related (one conjunctival erosion, one tube retraction, one tube with tip damage). There was one case of hyphema and one case of Descemet's membrane detachment; the latter was treated successfully with anterior chamber gas injection at the slit lamp. Of the eight eyes with complications, three required treatment in the operating room (three tuberelated complications). None of the eyes undergoing Baerveldt shunt implantation required further glaucoma surgery during the first year of follow-up. In the DS group, 20 % of eyes experienced postoperative Seidel-positive wound leak (n=11); half of these lasted less than 1 week (n=6), and one eye required surgical revision. Other complications were hypotony-related: four eyes with choroidal detachment and one hypotony maculopathy.
Postoperative interventions
In the DS group, 41 % (n = 24) required at least one goniopuncture, 9 % (n=5) required needling revision at the slit lamp, and 43 % (n=25) required subconjunctival antimetabolite injections (Table 4 ). In the BGI group, ligature suture lysis with an argon laser was required in 13 of the 18 eyes in which ligation had been performed. All eyes had occluding intraluminal stents to prevent hypotony. The mean time to Fig. 2 Kaplan-Meier cumulative failure curves for DS group (gray/solid lines) and BGI group (black/dashed lines). The difference between the failure curves of the DS and BGI groups was assessed using the log-rank statistic; the associated p value was 0.07 occlusive stent removal after surgery was 17 weeks. In 17 % (10 eyes), removal of the stent was not required; in 64 % (37 eyes), total stent removal was performed, and in 19 % (n=11), partial stent removal was performed due to risk factors for hypotony. In eight of these, total stent removal was required at a later date. One eye in the BGI group required viscoelastic injection at the slit lamp and one eye required bleb needling. The majority of DS eyes (n=45, 78 %) underwent a single surgical procedure; 13 (22 %) eyes underwent combined surgery (with phacoemulsification). There were no significant differences in IOP, complications, number of interventions or failure rates between eyes that underwent DS alone and those that underwent combined surgery (p>0.3). This was likewise the case for the BGI group, where 53 eyes underwent a single surgical procedure and 5 (9 %) eyes underwent combined surgery.
Mitomycin C (MMC) was used intraoperatively in the majority of eyes in the DS group (n=47; 81 %). At 1 year postoperatively, there were no differences in failure or complications rates between DS eyes that received MMC intraoperatively and those that did not (p>0.1).
Discussion
This is the first study to compare surgical failure rates and complications following Baerveldt shunt implantation and deep sclerectomy. A greater reduction in IOP was observed following repeat DS in the first 3 months postoperatively. The IOP reduction in the BGI group continued up to 6 months postoperatively, coinciding with the removal of flow restrictors (occlusive stents). By 12 months, median IOP was significantly lower in the BGI than the DS group, which may have important implications for strategies to reduce the progression of glaucoma [28] . A common definition of surgical failure is a reduction in IOP of less than 20 % from baseline or outside the range of 5 to 21 mmHg [19] [20] [21] . Using this criterion, a lower rate of surgical failure was observed in the BGI group, which approached statistical significance (p=0.07).
A significantly greater number of postoperative complications were observed following repeat DS (41 %) than BGI (14 %). Complications in both groups were usually transient and did not result in permanent visual loss. Complication rates of repeat DS have not been previously reported, but considering previous reports on repeat trabeculectomy [19] , these were expected to be greater than those with primary surgery (32-49 complications per 100 eyes; Table 3 ) [7, 8, 10] . In recent multicentre trials, complication rates for Baerveldt tube implantation [26] 0 (0) 0 [11] The indexed number is the associated reference number of the report in which this complication rate was published. BGI Baerveldt glaucoma implant, DS deep sclerectomy, NA not applicable were higher than those reported here (ranging between 34 and 58 %; Table 3 ); however, approximately half of the reported complications were hypotony-related [20, 22, 23, 25] . In the present report, the BGI shunt implantation technique and postoperative management were specifically modified to reduce postoperative hypotony-related complications [15, 29] . Glaucoma surgery is a known risk factor for cataract progression, with the possible exception of nonpenetrating surgical procedures [2, 17] . In the present report, visual acuity remained stable during the first year in both groups, although the reason for this may have differed between groups: DS may not have induced cataract formation, whereas most patients in the BGI group were pseudophakic at the time of surgery.
A significant difference between groups was observed in baseline preoperative VA, which could indicate selection bias between samples. The lower VA in the BGI group suggests more advanced disease, which may also imply a longer duration of glaucoma medication use. There was no difference, however, in the mean number of preoperative medications.
Retrospective studies are known to result an undersampling of data and under-reporting of complications; this is an obvious weakness of the current study. However, both groups suffered equally from this weakness, as all surgery was performed in the same tertiary centre. Overall, these results indicate reduced surgical success in eyes undergoing repeat DS, similar to previous reports on repeat trabeculectomy [19, 20] . However, these results must be confirmed in prospective randomised studies.
Conclusions
Eyes with Baerveldt shunt implants experienced a greater reduction in IOP and fewer complications at 1 year postoperatively. This supports Minckler's supposition that aqueous tube implantation should be considered when planning second-line glaucoma surgery [14] .
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